113 related articles for article (PubMed ID: 12419382)
1. Six-membered cyclic ureas as HIV-1 protease inhibitors: a QSAR study based on CODESSA PRO approach. Quantitative structure-activity relationships.
Katritzky AR; Oliferenko A; Lomaka A; Karelson M
Bioorg Med Chem Lett; 2002 Dec; 12(23):3453-7. PubMed ID: 12419382
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors.
Gupta SP; Babu MS; Garg R; Sowmya S
J Enzyme Inhib; 1998 Sep; 13(6):399-407. PubMed ID: 9825304
[TBL] [Abstract][Full Text] [Related]
3. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
[TBL] [Abstract][Full Text] [Related]
5. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
Garg R; Bhhatarai B
Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
[TBL] [Abstract][Full Text] [Related]
6. Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
Garg R; Patel D
Bioorg Med Chem Lett; 2005 Aug; 15(16):3767-70. PubMed ID: 15993582
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
[TBL] [Abstract][Full Text] [Related]
9. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.
Avram S; Bologa C; Flonta ML
J Mol Model; 2005 Mar; 11(2):105-15. PubMed ID: 15714296
[TBL] [Abstract][Full Text] [Related]
10. A simple clustering technique to improve QSAR model selection and predictivity: application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(6):2180-93. PubMed ID: 14632470
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.
De Lucca GV; Liang J; Aldrich PE; Calabrese J; Cordova B; Klabe RM; Rayner MM; Chang CH
J Med Chem; 1997 May; 40(11):1707-9. PubMed ID: 9171880
[TBL] [Abstract][Full Text] [Related]
12. Tricyclic ureas: a new class of HIV-1 protease inhibitors.
Han W; Pelletier JC; Hodge CN
Bioorg Med Chem Lett; 1998 Dec; 8(24):3615-20. PubMed ID: 9934481
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
14. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
[TBL] [Abstract][Full Text] [Related]
15. Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease.
Garg R; Bhhatarai B
J Comput Aided Mol Des; 2008 Oct; 22(10):737-45. PubMed ID: 18368496
[TBL] [Abstract][Full Text] [Related]
16. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
De Lucca GV; Liang J; De Lucca I
J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
[TBL] [Abstract][Full Text] [Related]
17. A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors.
Gupta SP; Babu MS; Sowmya S
Bioorg Med Chem; 1998 Nov; 6(11):2185-92. PubMed ID: 9881109
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.
Yadav D; Paliwal S; Yadav R; Pal M; Pandey A
PLoS One; 2012; 7(11):e48942. PubMed ID: 23145032
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Debnath AK
J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
